GPX4 and metabolic dysfunction-associated steatotic liver disease: ACSL4 knockout downregulated lipid peroxidation and inhibited ACSL4/p38 MAPK/GPX4 pathway-mediated ferroptosis, ultimately inhibiting NAFLD progression [194].